Restore Vision Raises $1.3 billion Series B
Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases raised $1,300M in Series B financing. Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases is a Digital Health company focused on Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）. The new capital is framed around Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）.
What it does
Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases is a Digital Health company focused on Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）. Management framed the new capital around Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）.
Trend impact
Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases aims to displace fragmented care delivery and legacy clinician workflow software with AI-enabled healthcare tooling. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.
Funding history
- April 16, 2026 · Series B · $1.3 billion · undisclosed investors
Products & services
- Development capability
- News Releases capability
- Restore Vision Inc.. Development of gene-agnostic optogenetic capability
- Yusaku Katada, CEO of Restore Vision capability
- Taking advantage of the regulatory landscape in Japan, we are building capability